PIK3CA and non-small cell lung carcinoma: We found that sorafenib prevented the emergence of cells harboring KRAS-G12D, BRAF-V600E, or PIK3CA-E545K, in both PC9 cells (Fig. 2A) and other NSCLC cell models, including PDCs (Fig. 2B and Supplementary Fig. 2A–C).